Abstract
336 (PB-131) - Adjuvant pertuzumab (PER) for HER2-positive early stage breast cancer (eBC): A Swiss experience
Full Text
Sign-in/Register to access full text options
Published version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have